250 related articles for article (PubMed ID: 21647886)
1. Multidimensional methods for the formulation of biopharmaceuticals and vaccines.
Maddux NR; Joshi SB; Volkin DB; Ralston JP; Middaugh CR
J Pharm Sci; 2011 Oct; 100(10):4171-97. PubMed ID: 21647886
[TBL] [Abstract][Full Text] [Related]
2. An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability.
Maddux NR; Rosen IT; Hu L; Olsen CM; Volkin DB; Middaugh CR
J Pharm Sci; 2012 Jun; 101(6):2017-24. PubMed ID: 22447621
[TBL] [Abstract][Full Text] [Related]
3. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
J Pharm Sci; 2013 Jan; 102(1):62-72. PubMed ID: 23150484
[TBL] [Abstract][Full Text] [Related]
4. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb.
Gruia F; Du J; Santacroce PV; Remmele RL; Bee JS
J Pharm Sci; 2015 Apr; 104(4):1539-42. PubMed ID: 25270279
[TBL] [Abstract][Full Text] [Related]
5. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
6. Technical decision-making with higher order structure data: specific binding of a nonionic detergent perturbs higher order structure of a therapeutic monoclonal antibody.
Budyak IL; Doyle BL; Weiss WF
J Pharm Sci; 2015 Apr; 104(4):1543-7. PubMed ID: 25545760
[TBL] [Abstract][Full Text] [Related]
7. Effects of surfaces and leachables on the stability of biopharmaceuticals.
Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN
J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787
[TBL] [Abstract][Full Text] [Related]
8. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.
Houde D; Berkowitz SA; Engen JR
J Pharm Sci; 2011 Jun; 100(6):2071-86. PubMed ID: 21491437
[TBL] [Abstract][Full Text] [Related]
9. High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.
Alsenaidy MA; Kim JH; Majumdar R; Weis DD; Joshi SB; Tolbert TJ; Middaugh CR; Volkin DB
J Pharm Sci; 2013 Nov; 102(11):3942-56. PubMed ID: 24114789
[TBL] [Abstract][Full Text] [Related]
10. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.
Li Y; Mach H; Blue JT
J Pharm Sci; 2011 Jun; 100(6):2120-35. PubMed ID: 21491438
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Protein-Excipient Microheterogeneity in Biopharmaceutical Solid-State Formulations by Confocal Fluorescence Microscopy.
Koshari SH; Ross JL; Nayak PK; Zarraga IE; Rajagopal K; Wagner NJ; Lenhoff AM
Mol Pharm; 2017 Feb; 14(2):546-553. PubMed ID: 28094996
[TBL] [Abstract][Full Text] [Related]
12. Protein particulate detection issues in biotherapeutics development--current status.
Das TK
AAPS PharmSciTech; 2012 Jun; 13(2):732-46. PubMed ID: 22566174
[TBL] [Abstract][Full Text] [Related]
13. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
14. Factors to Govern Soluble and Insoluble Aggregate-formation in Monoclonal Antibodies.
Fukuda J; Iwura T; Yanagihara S; Kano K
Anal Sci; 2015; 31(12):1233-40. PubMed ID: 26656811
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of protein stability in rod-insert vaginal rings.
Pattani A; Lowry D; Curran RM; McGrath S; Kett VL; Andrews GP; Malcolm RK
Int J Pharm; 2012 Jul; 430(1-2):89-97. PubMed ID: 22486955
[TBL] [Abstract][Full Text] [Related]
16. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
18. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.
Peek LJ; Brey RN; Middaugh CR
J Pharm Sci; 2007 Jan; 96(1):44-60. PubMed ID: 16998874
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Propylene Glycol-Mitigated Freeze/Thaw Agglomeration of a Frozen Liquid nOMV Vaccine Formulation by Static Light Scattering and Micro-Flow Imaging.
Mensch CD; Davis HB; Blue JT
PDA J Pharm Sci Technol; 2015; 69(4):477-98. PubMed ID: 26242785
[TBL] [Abstract][Full Text] [Related]
20. Antibody structure, instability, and formulation.
Wang W; Singh S; Zeng DL; King K; Nema S
J Pharm Sci; 2007 Jan; 96(1):1-26. PubMed ID: 16998873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
